ProQR Therapeutics (PRQR) Cash & Equivalents (2012 - 2026)

ProQR Therapeutics (PRQR) has reported Cash & Equivalents for 15 consecutive years, with $92.3 million the latest figure, recorded in Q1 2026.

• Quarterly Cash & Equivalents fell 38.75% year-over-year to $92.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $92.3 million (down 38.75% YoY) and the FY2025 annual result came in at $105.2 million, down 38.15% from the prior year.
• Cash & Equivalents retreated to $92.3 million in Q1 2026 per PRQR's latest filing, from $105.2 million in the prior quarter.
• Over the last five years, Cash & Equivalents for PRQR reached as high as $190.7 million in Q1 2022 and fell as low as $89.9 million in Q2 2024.
• A 5-year average of $131.4 million and a median of $135.3 million in 2023 frame the typical range for Cash & Equivalents.
• The largest YoY upside for Cash & Equivalents was 146.93% in 2022 against a maximum downside of 49.46% in 2022.
• Year by year, Cash & Equivalents stood at $107.8 million in 2022, then rose by 25.48% to $135.3 million in 2023, then rose by 25.63% to $170.0 million in 2024, then sank by 38.15% to $105.2 million in 2025, then retreated by 12.24% to $92.3 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $92.3 million, $105.2 million, and $121.6 million for Q1 2026, Q4 2025, and Q3 2025 respectively.